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Abstract
Background: Pleiotrophin (PTN) is a cytokine found highly upregulated in the brain in different disorders characterized
by overt neuroinflammation such as neurodegenerative diseases, drug addiction, traumatic injury, and ischemia. In the
present work, we have explored whether PTN modulates neuroinflammation and if Toll-like receptor 4 (TLR4), crucial in
the initiation of an immune response, is involved.
Methods: In immunohistochemistry assays, we studied lipopolysaccharide (LPS, 7.5 mg/kg i.p.)-induced changes in
glial fibrillary acidic protein (GFAP, astrocyte marker) and ionized calcium-binding adaptor molecule 1 (Iba1, microglia
marker) expression in the prefrontal cortex (PFC) and striatum of mice with transgenic PTN overexpression in the brain
(PTN-Tg) and in wild-type (WT) mice. Cytokine protein levels were assessed in the PFC by X-MAP technology.
The influence of TLR4 signaling in LPS effects in both genotypes was assessed by pretreatment with the TLR4
antagonist (TAK-242, 3.0 mg/kg i.p.). Murine BV2 microglial cells were treated with PTN (0.5 μg/ml) and LPS (1.0 μg/ml)
and assessed for the release of nitric oxide (NO).
Results: We found that LPS-induced microglial activation is significantly increased in the PFC of PTN-Tg mice
compared to that of WT mice. The levels of TNF-α, IL-6, and MCP-1 in response to LPS were significantly increased in
the PFC of PTN-Tg mice compared to that of WT mice. Pretreatment with TAK-242 efficiently blocked increases in
cytokine contents in a similar manner in both genotypes. Concomitant incubation of BV2 cells with LPS and PTN
significantly potentiated the production of NO compared to cells only treated with LPS.
Conclusions: Our findings identify for the first time that PTN is a novel and potent regulator of neuroinflammation.
Pleiotrophin potentiates LPS-stimulated microglia activation. Our results suggest that regulation of the PTN signaling
pathways may constitute new therapeutic opportunities particularly in those neurological disorders characterized by
increased PTN cerebral levels and neuroinflammation.
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Background
Inflammation is a key event in the healing process of the
damaged tissue, and activation of the innate immune
system is fundamental in the response to inflammation.
When prolonged, however, inflammation can become
deleterious. Within the central nervous system (CNS),
the two main players in neuroinflammation are glial
cells: microglia, the resident macrophages in the CNS,
and astrocytes [1]. Toll-like receptors (TLRs), which are
expressed in the rodent microglia and astrocytes [2], are
key molecules in the activation of innate immunity during
CNS damage. Activation of TLRs triggers the downstream
stimulation of nuclear factor-κB (NFκB) and the induction
of genes that encode inflammation-associated molecules
and cytokines including TNF-α, IL-1β, IL-6, iNOS, and
COX2 [2–4].
Ever-growing evidence points to a key role of in-
flammatory processes in a broad spectrum of diseases
including traumatic brain injury, chronic neurodegenera-
tive diseases, neuropathic pain, ischemia, and neuro-
psychiatric disorders including drug addiction [5–7].
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Psychostimulants such as amphetamine and its derivatives
cause neuroinflammation and limit neurogenesis and in-
duce blood-brain barrier (BBB) damage [8, 9]. All these ef-
fects induced by amphetamines are important for the
dopaminergic injury induced by these drugs in the nigros-
triatal pathway [10], which is the same circuitry affected in
Parkinson’s disease (PD). Interestingly, recent evidence in-
dicate a 3-fold increased risk of PD in these drug addicts
[11], suggesting that common pathogenic mechanisms
could underlie both diseases, PD and amphetamines
abuse, one of which could be neuroinflammation [9, 12].
In the search for validation of new biomarkers and for the
development of new drugs that could modulate the in-
flammatory processes underlying these and other diseases
of the CNS [13], our strategy was to identify proteins with
known regulatory functions in inflammation, whose levels
of expression are upregulated after amphetamine adminis-
trations and in the neurodegenerative areas of the brain of
PD patients.
Pleiotrophin (PTN) is a cytokine that is upregulated in
different brain areas after administration of different drugs
of abuse including amphetamine [14, 15] and in the
nigrostriatal pathway of patients with PD [16]. PTN is im-
portant for CNS repair and for survival and differentiation
of dopaminergic neurons [6]. In addition, evidence points
to a modulatory role of PTN on inflammation. In periph-
eral organs, PTN is known to induce inflammatory media-
tors [17] and its expression levels are significantly reduced
by administration of anti-inflammatory drugs [18]. Little is
known about a possible role of PTN on neuroinflamma-
tion. Transgenic mice with PTN overexpression in the
brain (PTN-Tg) show a ~4-fold increased amphetamine-
induced striatal astrogliosis compared to wild-type (WT)
mice [19]. However, PTN genetically deficient (PTN-/-)
mice show a modest ~20% increase in amphetamine-
induced astrocytosis, possibly reflecting proinflammatory
compensatory mechanisms [19–21]. We hypothesize that
PTN is a novel modulator of neuroinflammation. To test
this hypothesis, we have now comparatively studied the
astrocytic response, microglial activation, and cytokine re-
lease induced by lipopolysaccharide (LPS) in PTN-Tg and
in WT mice. Since previous studies suggest a possible
contribution of PTN to Toll-like receptor 4 (TLR4)-medi-
ated immune response [22] and TLR4 plays a pivotal role
in neuroinflammation, we have also investigated the pos-
sible differential contribution of TLR4 to the neuroinflam-
matory processes induced by LPS in both genotypes.
Methods
Animals
PTN-Tg mice on a C57BL/6J background were generated
by pronuclear injection as previously described [23, 24].
The acceptor vector contained the regulatory regions re-
sponsible for tissue-specific expression of Thy-1 gene,
which drives neuron-specific expression of transgenes
[25, 26]. PTN-specific overexpression in different
brain areas, including an ~3–4-fold upregulation in the
prefrontal cortex (PFC) and a 20% increase of PTN pro-
tein levels in striatum, was established by quantitative
real-time polymerase chain reaction (qRT-PCR), in situ
hybridization, and by western blot [23, 27, 28].
We used male PTN-Tg and WT animals of 9–10 weeks
(20-25 g). Mice were housed under controlled environ-
mental conditions (22 ± 1 °C and a 12-h light/12-h dark
cycle) with free access to food and water.
All the animals used in this study were maintained in
accordance with the European Union Laboratory Animal
Care Rules (86/609/ECC directive), and the protocols
were approved by the Animal Research Committee of
USP-CEU.
Treatments
To test genotypic differences in LPS-induced neuroin-
flammation and the involvement of TLR4 in LPS effects
in PTN-Tg and WT mice, we assessed the effects of LPS
in mice pretreated with the TLR4 antagonist TAK-242
(Merck Millipore, Madrid, Spain). For this purpose, mice
were injected (i.p.) with TAK-242 (3 mg/kg) or saline
(10 ml/kg; control) 30 minutes before a single i.p. injec-
tion of LPS (7.5 mg/kg) or saline (10 ml/kg; control). As a
result, we obtained four experimental groups in both ge-
notypes: saline + saline (Sal-Sal), saline + LPS (Sal-LPS),
TAK-242 + saline (TAK-Sal), and TAK-242 + LPS
(TAK-LPS). For immunohistochemistry analysis, ani-
mals were sacrificed 16 h after LPS or last saline adminis-
tration (n = 4–5/group/genotype) by perfusion with 4%
p-formaldehyde. For tisular analysis of cytokine levels,
animals were decapitated 16 h after LPS or the last saline
administration (n = 5/group/genotype) and the PFC was
rapidly removed and frozen in dry ice and stored to −80 °C
until the protein extraction procedure.
Immunohistochemistry analysis
Mice were transcardially perfused with 4% p-formaldehyde;
the brains were removed and conserved in p-formaldehyde
for 24 h and then transferred to a 30% sucrose solution
containing 0.02% sodium azide for storage at 4 °C; 30-μm
PFC and striatal free-floating sections were processed as
previously described [20, 21, 29]. Immunohistochemistry
studies were performed in one slice per 180 μm (the PFC
from the bregma −3.08 mm to −2.46 mm; the striatum
from the bregma 1.54 mm to −0.10 mm).
In order to study gliosis, sections were incubated over-
night at 4 °C with anti-glial fibrillary acidic protein
(GFAP; Millipore, Madrid, Spain; 1:1000) and anti-
ionized calcium-binding adaptor molecule 1 (Iba1,
Wako, Osaka, Japan; 1:1000) antibodies, following by 30-
min incubation with the Alexa-Fluor-555 and Alexa-Fluor-
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488 corresponding secondary antibody (Invitrogen,
Waltham, MA, USA; 1:500). Sections were mounted on
gelatin-coated slides and coverslipped with Fluoromount
medium. Photomicrographs were captured with a digital
camera coupled to an optical microscope (DM5500B,
Leica, Solms, Germany). Analysis was performed using
ImageJ (NIH, Bethesda, MD, Version 1.50f), in the three
most central slices of each area. Iba1+ cells and GFAP+
astrocytes were counted in whole sections of the PFC and
in 1100 μm× 1400 μm standardized areas in the striatum
as previously described [21, 29]. In the case of Iba1-ir,
total marked area was calculated as overall image fluor-
escence, subtracting the mean background fluores-
cence. Computer-based analysis of the morphology of
individual Iba1+ cells was performed using the
“Analyze Particle” function in ImageJ software. Images
were segmented and smoothed to best fit cell shape. To
be sure to select only cells entirely present in the acquired
field, cells with an area of >25 μm2 were analyzed. The ob-
jects meeting the minimum size to be analyzed were mea-
sured for the following parameters: area, perimeter, and
circularity. The soma size (cell area) is expressed in square
micrometers. The perimeter was calculated based on the
outline length of a given object. It measures the length
around the periphery of each soma and is expected to be
higher in activated and hypertrophic cells. Circularity was
calculated by the following formula: 4π × (area/perim-
eter2). This parameter varies from 0 (linear polygon) to 1
(perfect circular object). Mean single-cell values for each
parameter were used for statistics.
Cytokine levels
Approximately 5 mg of each sample of the PFC (n = 5/
group) was homogenized in 100 μl of homogenization buf-
fer (0.05% Tween 20 and protease inhibitor cocktail
(Thermo Fisher Scientific Inc., Waltham, MA, USA) in
PBS, pH 7.2). After 3 cycles of 1 min and 50 Hz in the tis-
suelyzer (Quiagen, Germantown, Maryland, USA), samples
were centrifuged at 11000×g for 30 min at 4 °C. After cen-
trifugation, supernatants were transferred to a new tube
and stored at −80 °C until the assay. Total protein content
of each sample was measured using the BCA protein assay
kit (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Levels of tumor necrosis factor-α (TNF-α), interleukin 1β
(IL-1β), interleukin 6 (IL-6), monocyte chemoattractant
protein-1 (MCP-1), interleukin 4 (IL-4), and interleukin 10
(IL-10) were measured by X-Map technology using a Milli-
plex MADPK-71K adipokine kit according to the manufac-
turer’s description (Merck Millipore, Spain).
BV2 cell cultures
BV2 murine microglial cells
BV2 murine microglial cells were a generous gift from
Professor Antonio Cuadrado (Instituto de Investigaciones
Biomédicas “Alberto Sols” (IIBM), Madrid, Spain). Cells
were routinely maintained in RPMI-1640 medium with
fetal bovine serum (10%), penicillin (100 U/ml), strepto-
mycin (100 μg/ml), and L-glutamine (4 mM) at 37 °C in
5% CO2 humidified air following conditions used by
others [30, 31]. Prior to each experiment, cells were grown
for 24 h on 96-well plates at a concentration of 1 × 104
cells per well.
Measurement of NO production
Nitric oxide (NO) production was quantified by nitrite
accumulation in the culture medium using the Griess re-
active (2.25% sulfanilamide and 0.22% N-(1-naphthyl)-
ethylenediamine dihydrochloride), according to protocols
previously described [32, 33]. After fasting the cells for
24 h, BV2 cells were stimulated with different concentra-
tions of PTN (0.05 μg/ml or 0.5 μg/ml), with or without
LPS (1.0 μg/ml), for another 24 h. The concentrations of
PTN were selected to correlate with the PTN overexpres-
sion in the brain of PTN-Tg mice and are within the range
of concentrations used before to test the effects of PTN in
neuronal injury [34] and in the expansion of human
stem cells [35]. The NO production by cells was
quantified in a microplate reader (Versa-Max, Molecular
Devices, Sunnyvale, CA, USA) at 540 nm and then calcu-
lated with reference to the standard curve generated with
NaNO2.
Statistics
Data are presented as mean ± standard error of the mean
(SEM). Data obtained from image analysis of the striatal
and PFC immunostaining and cytokine levels were ana-
lyzed using two-way ANOVA considering genotype and
treatment as variants. Relevant differences were analyzed
by post hoc comparisons with Bonferroni’s post hoc
tests. Data obtained from BV2 cells were analyzed using
one-way ANOVA followed by post hoc comparisons
with Tukey’s post hoc tests. P < 0.05 was considered as
statistically significant. All statistical analyses were per-
formed using Graph-Pad Prism program (San Diego,
CA, USA).
Results
Differential regulation of LPS-induced astrocytic and
microglial responses in the PFC of PTN-Tg mice. Effect of
TAK-242 on LPS-induced microglial response and changes
in cytokine contents in the PFC of PTN-Tg and WT mice
PTN is a cytokine highly upregulated in the brain in dif-
ferent CNS disorders characterized by neuroinflammation
[6]. We aimed to study the modulatory role of PTN over-
expression (3-fold) in the PFC of PTN-Tg mice [23, 24] on
LPS-induced neuroinflammation. To investigate proin-
flammatory responses in these experiments, we tested the
astrocytic and microglial response in PFC sections of WT
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and PTN-Tg mice treated with saline (Sal-Sal) or LPS
(Sal-LPS). Astrocyte activation was assessed by morph-
ology and expression of GFAP, an astrocyte-specific inter-
mediate filament protein [36]. LPS treatment tended to
increase the number of GFAP+ astrocytes in the PFC of
WT mice, being these cells characterized by large densely
stained cell bodies as well as long and extensive processes
compared to saline-treated animals (Fig. 1). In contrast,
these effects on GFAP+ IR induced by LPS were blocked
in PTN-Tg mice (Fig. 1).
Previous studies have linked LPS-induced activation of
microglia and production of proinflammatory factors to
brain damage and neurodegeneration [37]. To investigate
proinflammatory responses in this experiment, PFC sec-
tions were immunostained with anti-Iba1 microglial anti-
body. In the saline control groups, microglial cells have
resting morphology (Fig. 2a, Sal-Sal). Immunohistochemis-
try for Iba1 did not reflect significant changes in the num-
ber of Iba1+ cells in the PFC of WTand PTN-Tg mice after
LPS treatment (Fig. 2b). However, we observed a clearly
enhanced hypertrophism characterized by activation, soma
enlargement, and sprouting of new ramifications in LPS-
treated PTN-Tg mice compared to that in LPS-treated WT
mice and saline-treated mice from the same genotype
(Fig. 2a, Sal-LPS). Accordingly, the total marked area
(Fig. 2c) tended to increase in LPS-treated PTN-Tg mice
compared to that in saline-treated mice. As expected, the
Iba1+ cell area was increased in LPS-treated mice of both
genotypes compared with that in saline-treated mice
(Fig. 2d); however, LPS induced an increase in cell area that
was significantly enhanced in PTN-Tg mice compared to
that in WT mice (Fig. 2d). The increase in the perimeter
was also higher in LPS-treated PTN-Tg mice (Fig. 2e). The
decrease caused by LPS in the circularity index was more
pronounced in PTN-Tg mice (Fig. 2f). Overall, the data
demonstrate that LPS-induced microglial response is in-
creased in the PFC of PTN-Tg mice compared to that of
WT mice. Interestingly, we observed that the morpho-
logical changes induced by LPS in microglial cells of both
genotypes were not prevented by the previous administra-
tion of the TLR4 antagonist TAK-242 (Fig. 2, TAK-LPS).
We measured the contents of different cytokines in
the PFC of mice from both genotypes. Confirming the
neuroimmune response to LPS administration, we found
that the levels of proinflammatory cytokines such as
TNF-α, IL-6, and MCP-1 were many-fold upregulated in
the PFC of LPS-treated WT mice compared to those of
the saline-treated group (Fig. 3, Sal-LPS vs. Sal-Sal).
More importantly, we found a highly significant ~7-fold
upregulation of the levels of TNF-α in the PFC of LPS-
treated PTN-Tg mice compared to that of WT mice
(Fig. 3). Similarly, the levels of IL-6 in the PFC of LPS-
treated PTN-Tg mice were increased compared to those
of WT mice (Fig. 3). Interestingly, pretreatment with
TAK-242 efficiently blocked LPS-induced increases of
TNF-α and IL-6 in the PFC of mice from both genotypes
(Fig. 3, Sal-LPS vs. TAK-LPS). In addition, we found signifi-
cantly higher levels of MCP-1 in the PFC of LPS-treated
PTN-Tg mice compared to those of WT mice although, in
this case, LPS effect on MCP-1 levels was partially blocked
by previous administration of TAK-242 in both genotypes
(Fig. 3). In contrast, we did not observe relevant genotypic
differences in the levels of IL-1β (Fig. 3). Concerning the
anti-inflammatory cytokines IL-10 and IL-4, we did not
find genotype- or treatment-related significant differences
in their contents in the PFC of LPS-treated PTN-Tg mice
compared to those of WT mice (Fig. 3).
Overall, the data demonstrate that LPS-induced
microglial activation is enhanced in the PFC of PTN-Tg
mice compared to that of WT animals. Interestingly, the
data suggest that TLR4 activation is crucial for LPS-
induced cytokine release in both genotypes but does not
play a significant role in LPS-induced microglial mor-
phological response in either genotype.
Fig. 1 LPS effects on astrocytosis in the PFC of WT and PTN-Tg mice.
Photomicrographs are from GFAP-immunostained PFC sections of
saline + saline (Sal)- or saline + LPS (LPS)-treated animals (n = 4–5/
group). Higher magnification images in the lower right corner of
every representative picture show that astrocytes were hypertrophic
and densely stained in WT mice treated with LPS. The graph
represents quantification of data obtained from the counts of GFAP-
positive cells in PFC whole sections. ##P < 0.01 vs. WT-LPS. Scale bar
= 500 μm, (high magnification, scale bar = 50 μm). SAL saline, LPS
lipopolysaccharide, WT wild-type mice, PTN-Tg mice with transgenic
pleiotrophin overexpression in the brain, GFAP glial fibrillary
acidic protein
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Effects of TAK-242 and LPS in the striatum of WT and
PTN-Tg mice
To investigate the effects of a more modest PTN overex-
pression (~20%, PTN-Tg mouse striatum) [28] on LPS-
induced neuroinflammation, we tested the astrocytic and
microglial response in striatal sections of WTand PTN-Tg
mice treated with saline (Sal-Sal) or LPS (Sal-LPS). We
did not find genotypic- or treatment-related significant
differences in the number of GFAP+ cells between
groups (Fig. 4). Similarly to PFC, LPS treatment tended
to increase the number of GFAP+ cells in the striatum
of WT mice, whereas this tendency was absent in PTN-
Tg mice (Fig. 4). Concerning microglia (Fig. 5),
immunohistochemistry for Iba1 did not reflect signifi-
cant changes in the number of Iba1+ cells or in the
total marked area in the striatum of WT and PTN-Tg
mice after LPS treatment (Fig. 5a, b, c). However, signs
of hypertrophism, soma enlargement, and sprouting of
new ramifications in LPS-treated animals were
observed in both genotypes compared to those in
saline-treated groups (Fig. 5a). The Iba1+ cell area was
significantly increased in both genotypes but especially
in LPS-treated PTN-Tg mice compared to that in WT
mice (Fig. 5d). On the other hand, the increase in the
perimeter was higher in LPS-treated WT mice (Fig. 5e),
whereas no differences between groups were found in
Fig. 2 Effects of TAK-242 and LPS on microglia activation in the PFC of PTN-Tg mice. Photomicrographs are from Iba-1-immunostained PFC sections
of saline (Sal)- or TAK-242 (TAK)-pretreated and saline (Sal)- or LPS-treated animals (n = 4–5/group) (a). Graphs represent quantification of
data (mean ± SEM) obtained from the counts of Iba-1-positive cells (b), total marked area (c), cell area (d), soma perimeter (e), and circularity index (f) in
PFC whole sections. *P< 0.05, ***P< 0.001, ****P < 0.0001 vs. Sal + Sal within the same genotype. #P< 0.05, ##P< 0.01 vs. WT within the same treatment.
Scale bar = 100 μm. SAL saline, LPS lipopolysaccharide, TAK TAK-242, WT wild-type mice, PTN-Tg mice with transgenic pleiotrophin overexpression in the
brain, Iba1 ionized calcium-binding adaptor molecule 1
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the case of the circularity index (Fig. 5f ). We did not
observe significant effects of pretreatment with TAK-
242 on LPS-induced effects on microglia (Fig. 5). Over-
all, the data demonstrate that LPS-induced microglial
response in the striatum is more modest than that in
the PFC and that the moderate PTN overexpression in
this brain area of PTN-Tg mice does not play a signifi-
cant modulatory role on LPS effects.
Pleiotrophin potentiates NO production in LPS-stimulated
BV2 cells
To test the possible direct effects of PTN on murine
microglia in vitro, we investigated its effects on the pro-
duction of NO, which is a key inflammatory mediator in
LPS-stimulated BV2 microglia. First, we did not detect
any effect in BV2 cells incubated with PTN alone (0.05
and 0.5 μg/ml, Fig. 6). LPS (1.0 μg/ml) induced a signifi-
cant increase in the production of NO compared with
control cells (Fig. 6). Concomitant incubation of BV2
cells with LPS (1.0 μg/ml) and PTN (0.5 μg/ml) signifi-
cantly potentiated the production of NO compared to
cells only treated with LPS (Fig. 6).
Discussion
Pleiotrophin is a cytokine that is found highly upregu-
lated in diverse pathologies of the CNS characterized by
overt neuroinflammation including neurodegenerative
diseases, addictive disorders, ischemia, and neuropathic
pain [6, 38, 39]. The goal of this study was to investigate
whether pleiotrophin regulates the astrocytic response
and the activation of microglia in the brain after an in-
flammatory challenge. We used the systemic LPS treat-
ment acute inflammation murine brain model. In the in
vivo study, we found that LPS induced a moderate in-
crease in the number of GFAP+ astrocytes in the PFC
and striatum of WT mice. After LPS treatment, astro-
cytes appear hypertrophic, particularly in the PFC, sug-
gesting a LPS-induced upregulation of GFAP protein
concentrations in astrocytes of WT mice. This response
was significantly reduced in the PFC of LPS-treated
PTN-Tg mice, an area with a more significant PTN over-
expression in this genotype [24]. We previously found a
small (~20%) increase of striatal GFAP+ astrocytes in
amphetamine-treated PTN knockout (PTN-/-) mice
which could be attributed to compensatory mechanisms
Fig. 3 Effects of TAK-242 and LPS on cytokine expression in the PFC of PTN-Tg mice. TNF-α, Il-1β, IL-6, MCP-1, IL-4, and IL-10 protein levels measured
using a Milliplex system in PFC of mice pretreated with saline (Sal) or TAK-242 (TAK) and treated with saline (Sal) or LPS (n = 5/group). *P < 0.05,
***P < 0.001 vs. Sal + Sal within the same genotype. ##P < 0.01, ###P < 0.001 vs. WT within the same treatment. &&P < 0.01, &&&P < 0.001 vs. Sal
+ LPS within the same genotype. SAL saline, LPS lipopolysaccharide, TAK TAK-242, WT wild-type mice, PTN-Tg mice with transgenic pleiotrophin
overexpression in the brain, TNF Tumor necrosis factor-α, IL-1β interleukin 1β, IL-6 interleukin 6, MCP-1 monocyte chemoattractant protein-1, IL-4
interleukin 4, IL-10 interleukin 10
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[19, 21]. Interestingly, we recently found a highly signifi-
cant (13-fold) increase in the number of GFAP+ astro-
cytes in amphetamine-treated PTN-Tg mice suggesting
an enhanced neuroinflammatory response induced by
amphetamine in the presence of higher levels of PTN
[19]. Taking together, these data suggest that PTN differ-
entially regulates the astrocytic response depending on
the inflammatory stimulus.
Although upregulation of GFAP in astrocytes is con-
sidered an indicator of reactive astrogliosis and neuroin-
flammation, the regulation by PTN of two key elements
of neuroinflammation, microglia activation, and cyto-
kines release had not been tested before. In WT mice,
LPS tended to increase the perimeter of Iba1+ cells and
induced a significant increase in these cells area in the
PFC, indicating the presence of hypertrophic microglia.
In addition, LPS induced significant increases in the
levels of TNF-α, IL-6, and MCP-1 in WT mice confirm-
ing LPS-induced neuroinflammation in normal mice.
Interestingly, we found that PTN overexpression en-
hances microglial cell morphological changes to an
activated-form in the PFC of LPS-treated PTN-Tg mice
compared to that of WT mice. This was accompanied
by more pronounced LPS-induced increases of TNF-α,
IL-6, and MCP-1 in PTN-Tg mice compared to WT ani-
mals, indicating an important role of PTN on microglial
activation and neuroinflammation. Interestingly, the
TLR4 antagonist TAK-242 did not have any effect on
LPS-induced microglia morphological changes in either
genotype but efficiently blocked LPS-induced increases
of TNF-α, IL-6, and MCP-1 in both genotypes. This is
the first study showing that PTN overexpression in vivo
significantly potentiates LPS-induced microglial activa-
tion and neuroinflammation. It is important to note that
we did not find differences between genotypes in saline-
treated animals suggesting that PTN is an important
cytokine in the promotion of the effects triggered by the
inflammatory stimulus but does not trigger proinflamma-
tory cascades itself. Accordingly, our studies in vitro in
murine BV2 microglia cells demonstrate that incubation
with PTN alone does not cause significant effects on
microglia. However, PTN significantly enhanced LPS-
induced NO release in BV2 cells. Taking together, these
studies may be of relevance since PTN is found highly up-
regulated in different brain disorders characterized by
neuroinflammation such as Parkinson’s disease [16], Alz-
heimer’s disease [40], addictive disorders [14, 41, 42], tu-
mors [43], and ischemia [44]. However, we must be
cautious because the mechanisms involved in the short-
term inflammatory response induced by LPS might differ
substantially from those involved in the long-term inflam-
mation associated with the brain disorders mentioned
above. In the present work, we have demonstrated for the
first time that PTN potentiates microglial activation and
neuroinflammation after an acute exposure to the inflam-
matory stimulus. Additional studies are needed to describe
its role in chronic conditions of neuroinflammation.
Inflammation is a host defense mechanism mounted
to reduce injury. However, prolonged or uncontrolled in-
flammation can lead to tissue damage and destruction.
On the other hand, recent studies have shown that acti-
vated microglia contributes to the maintenance of tissue
homeostasis and protection of the CNS under various
pathological conditions [45]. Whether microglial activa-
tion primed by elevated levels of PTN contributes to the
deleterious or homeostatic effects of microglia needs to
be clarified. However, it has to be noted that one of the
mechanisms that microglia adopts to downregulate in-
flammation is the production of anti-inflammatory me-
diators such as IL-4 and IL-10, which suppress the
function of proinflammatory cytokines [46]. Here, we
demonstrate that the content of IL-10 and IL-4 is not af-
fected by increased PTN levels in the PFC of PTN-Tg
mice, whereas the proinflammatory cytokines TNF-α,
IL-6, and MCP-1 are highly upregulated compared to
WT mice treated with LPS. Thus, our data suggest that
high PTN levels lead activated microglia to promotion
of neuroinflammation rather than suppression.
Fig. 4 LPS effects on astrocytosis in the striatum of WT and PTN-Tg
mice. Photomicrographs are from GFAP-immunostained striatal
sections of saline + saline (Sal)- or saline + LPS (LPS)-treated animals
(n = 4–5/group). The graph represents quantification of data obtained
from the counts of GFAP-positive cells in the striatum. Scale bar =
200 μm. SAL saline, LPS lipopolysaccharide, WT wild-type mice, PTN-Tg
mice with transgenic pleiotrophin overexpression in the brain, GFAP
glial fibrillary acidic protein
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The mechanism of action of PTN supports our
findings. PTN binds receptor protein tyrosine phos-
phatase (RPTP) β/ζ (a.k.a. PTPRZ1) [47] and inacti-
vates its phosphatase activity. Inhibition of the
phosphatase activity of RPTPβ/ζ by PTN binding reg-
ulates the tyrosine phosphorylation of substrates of
RPTPβ/ζ that are known regulators of neuroinflam-
mation such as Fyn kinase [48]. After stimulation
with LPS, Fyn is activated in microglia by increased
phosphorylation in Y416 [48]. Activated Fyn phos-
phorylates PKCδ at Y311, contributing to an increase
in its kinase activity. The Fyn-PKCδ-signaling axis
further activates the LPS-induced MAP kinase phos-
phorylation and activation of the NFκB pathway, im-
plying that Fyn is a major upstream regulator of
proinflammatory signaling [48]. These signaling events
are observed as well in animal models of PD [48].
Previously, we demonstrated that PTN is a key modu-
lator of tyrosine phosphorylation of Fyn [49], suggest-
ing that PTN could be a major upstream regulator of
microglial neuroinflammatory processes in all those
neurological disorders in which significantly increased
levels of PTN have been detected by triggering
inflammogen-induced increase in Fyn kinase activity.
Fig. 5 Effects of TAK-242 and LPS on microglia activation in the striatum of PTN-Tg mice. Photomicrographs are from Iba-1-immunostained striatal
sections of saline (Sal)- or TAK-242 (TAK)-pretreated and saline (Sal)- or LPS-treated animals (n = 4–5/group) (a). Graphs represent quantification of
data (mean ± SEM) obtained from the counts of Iba-1-positive cells (b), total marked area (c), cell area (d), soma perimeter (e), and circularity index
(f) in the striatum. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Sal + Sal within the same genotype. Scale bar = 100 μm. SAL saline, LPS lipopolysaccharide,
TAK TAK-242, WT wild-type mice, PTN-Tg mice with transgenic pleiotrophin overexpression in the brain, Iba1 ionized calcium-binding adaptor
molecule 1
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Conclusions
Our findings identify for the first time that PTN is a
novel and potent regulator of neuroinflammation.
Pleiotrophin potentiates LPS-stimulated microglia ac-
tivation. Our results indicate that the regulation of
PTN signaling pathways may constitute new thera-
peutic opportunities particularly in those neurological
disorders characterized by increased PTN cerebral
levels and neuroinflammation.
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